FibroGen, Inc. to Present Phase 2 Data for FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), at American Society of Nephrology Kidney Week 2012

Published: Nov 01, 2012

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced that two abstracts relating to FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) clinical candidate for the treatment of anemia in chronic kidney disease, have been accepted for oral and poster presentations at the American Society of Nephrology (ASN) Kidney Week 2012. The annual meeting will be held October 30 – November 4, 2012, in San Diego, California. Full abstracts can be viewed online at

Back to news